About Us
Why Mighty Mito exists
Mighty Mito was born from one family's experience with an ultra-rare mitochondrial disease—and the realization that a diagnosis can be only the beginning of a very long road toward treatment.
When Felix was diagnosed with COX20-related mitochondrial complex IV deficiency, there was no approved treatment and no established roadmap for families like ours to follow.
We decided to help build one.
We started with a simple conviction: promising genetic therapies should have a path from the laboratory to the children who need them.
That belief now drives a nonprofit focused on accelerating the development and translation of therapies for ultra-rare mitochondrial diseases, beginning with COX20 deficiency.
Our work is grounded in scientific rigor, responsible stewardship, collaboration, and transparency.
Leadership
Mighty Mito is led by its founders and board of directors, who provide strategic direction, financial oversight, governance, and accountability as the organization grows. Board member profiles will be published here as our leadership team is finalized.
Board members — coming soon
Scientific & medical advisors
We are building a scientific and medical advisory council spanning mitochondrial disease, gene therapy, preclinical development, clinical translation, and regulatory strategy—helping ensure our decisions and priorities are grounded in rigorous science and the best available evidence.
Advisory council — coming soon
Institutional collaborators
Moving a therapy toward patients requires collaboration across researchers, academic institutions, clinicians, industry partners, and the broader rare-disease community. We work alongside those advancing COX20 gene-therapy research and development.
Collaborators — listed with permission
Build this mission with us.
We are early, and that is exactly why your support matters most right now.